英科智能有限公司
更新日：2023/06/12
主な応用分野
主要応用分野
Biotechnology
製品・サービス概要
Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research. We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
設立年
2018
会社番号
50759371
企業ステータス
事業継続中
チームの規模
0
実払資本金
0 (元/新台湾ドル)
登録住所
台湾
, 台北市
ウェブサイトリンク
設立年、会社形態、責任者、資本金、登記住所は「経済部商務発展司全国商工管理サービスポータル」より取得したものです。
会員限定コンテンツ
会員限定コンテンツです。閲覧するにはログインしてください
会社概要
Insilico Medicine was founded in 2014 and has developed state-of-the-art Artificial Intelligence platforms which allow for rapid identification of new molecular targets using multi-omics data and generation of novel compounds against targets by applying AI. Insilico established the HQ in Hong Kong and R&D offices in Taipei, Shanghai, and Europe. In 2020, Insilico Medicine was selected as the top 10 breakthrough technologies of the year. Later, Insilico announced a first-in-class preclinical candidate (PCC) targeting a novel target for Idiopathic Pulmonary Fibrosis (IPF) in 2021. The PCC nomination was completed every stage of drug discovery from target identification in only 18 months. With this amazing achievement, Insilico Medicine was recognized by known investors in biology and technology fields and received $255 million of round C for frontier research in the same year.
